博际生物医药科技

Boji Biopharmaceuticals is a clinical-stage biotechnology company dedicated to the discovery and development of innovative biologics for oncology. The company utilizes its proprietary Tumor Microenvironment Targeted (TMT) platform to develop therapies that localize immune activation within the tumor site, thereby enhancing efficacy and reducing systemic side effects. Its lead candidate, BJ-001, is a first-in-class tumor-targeted IL-15 fusion protein currently undergoing Phase 1 clinical trials in both the United States and China. Boji operates R&D and clinical facilities in Shanghai and San Francisco, facilitating a global development strategy for its pipeline of cytokines and multi-specific antibodies. The company is backed by leading venture capital firms and aims to provide transformative treatments for patients with advanced solid tumors. Boji's leadership team brings extensive experience from major global pharmaceutical companies, driving a robust portfolio of next-generation immunotherapies.